

Supplementary Table 2:
Tabulation of Samples from the Metastatic Melanoma Study

Patient ID	Flow Cytometry		TCR Sequencing	
	Week 0	Week 3	Week 0	Week 3
03015-01	x	x	x	x
03015-02	x	x	x	x
03015-03	x	x	x	x
03015-04	x	x	x	x
03015-05	x	x	x	x
03015-06	x	x	x	x
03015-07	x	x	x	x
03015-08	x	x	x	x
03015-09	x	x	x	x
03015-10	x	x	x	x
03015-11	x	x	x	x
03015-12	x	x	x	x
03015-13	x	x	x	x
03015-14	x	x	x	x
03015-15	x	x	x	x
03015-16	x	x	x	x
03015-18	x	x	x	x
03015-19	x	x	x	x
03015-20	x	x	x	x
03015-21	x	x	x	x
03015-23	x	x	x	x
Totals	21	21	14	14

x Sample was present and included in the analysis.

Supplementary Table 2:
Tabulation of Samples from the Metastatic Melanoma Study

Patient ID	Flow Cytometry		TCR Sequencing	
	Week 0	Week 3	Week 0	Week 3
03015-01	x	x	x	x
03015-02	x	x	x	x
03015-03	x	x	x	x
03015-04	x	x	x	x
03015-05	x	x	x	x
03015-06	x	x	x	x
03015-07	x	x	x	x
03015-08	x	x	x	x
03015-09	x	x	x	x
03015-10	x	x	x	x
03015-11	x	x	x	x
03015-12	x	x	x	x
03015-13	x	x	x	x
03015-14	x	x	x	x
03015-15	x	x	x	x
03015-16	x	x	x	x
03015-18	x	x	x	x
03015-19	x	x	x	x
03015-20	x	x	x	x
03015-21	x	x	x	x
03015-23	x	x	x	x
Totals	21	21	14	14

x Sample was present and included in the analysis.

Supplementary Table 2:
Tabulation of Samples from the Metastatic Melanoma Study

Patient ID	Flow Cytometry		TCR Sequencing	
	Week 0	Week 3	Week 0	Week 3
03015-01	x	x	x	x
03015-02	x	x	x	x
03015-03	x	x	x	x
03015-04	x	x	x	x
03015-05	x	x	x	x
03015-06	x	x	x	x
03015-07	x	x	x	x
03015-08	x	x	x	x
03015-09	x	x	x	x
03015-10	x	x	x	x
03015-11	x	x	x	x
03015-12	x	x	x	x
03015-13	x	x	x	x
03015-14	x	x	x	x
03015-15	x	x	x	x
03015-16	x	x	x	x
03015-18	x	x	x	x
03015-19	x	x	x	x
03015-20	x	x	x	x
03015-21	x	x	x	x
03015-23	x	x	x	x
Totals	21	21	14	14

x Sample was present and included in the analysis.